New drugs in ophthalmology: Metipranolol

Christina Flaxel, J. R. Samples

Research output: Contribution to journalArticle

Abstract

Metipranolol has been approved for the treatment of ocular conditions in which lowering of the IOP is likely to be of therapeutic benefit, including in patients with ocular hypertension and with chronic open angle glaucoma. It is presently marketed in 5 ml or 10 ml plastic ophthalmic bottle dispensers with a controlled drop tip as Optipranolol in a 0.3% concentration only. Metipranolol has been found to be equal in efficacy to 0.25% timolol. The major benefit to this drug is its potential savings over the other currently available beta blockers. For example, a 10 ml bottle of Timoptic 0.5% costs approximately $27.44 while a 10 ml bottle of Optipranolol costs $12.50 (a 45% savings). The foreseeable disadvantage to this drug is that it is only being marketed in the United States as a 0.3% solution, whereas the other nonselective beta blockers are available in two concentrations (0.25% and 0.5%).

Original languageEnglish (US)
Pages (from-to)171-174
Number of pages4
JournalJournal of Toxicology - Cutaneous and Ocular Toxicology
Volume10
Issue number3
StatePublished - 1991

Fingerprint

Metipranolol
Ophthalmology
Timolol
Bottles
Costs and Cost Analysis
Ocular Hypertension
Open Angle Glaucoma
Pharmaceutical Preparations
Plastics
Dispensers
Costs
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

New drugs in ophthalmology : Metipranolol. / Flaxel, Christina; Samples, J. R.

In: Journal of Toxicology - Cutaneous and Ocular Toxicology, Vol. 10, No. 3, 1991, p. 171-174.

Research output: Contribution to journalArticle

@article{8058d2b99e28446cb8fd9cb9bca52224,
title = "New drugs in ophthalmology: Metipranolol",
abstract = "Metipranolol has been approved for the treatment of ocular conditions in which lowering of the IOP is likely to be of therapeutic benefit, including in patients with ocular hypertension and with chronic open angle glaucoma. It is presently marketed in 5 ml or 10 ml plastic ophthalmic bottle dispensers with a controlled drop tip as Optipranolol in a 0.3{\%} concentration only. Metipranolol has been found to be equal in efficacy to 0.25{\%} timolol. The major benefit to this drug is its potential savings over the other currently available beta blockers. For example, a 10 ml bottle of Timoptic 0.5{\%} costs approximately $27.44 while a 10 ml bottle of Optipranolol costs $12.50 (a 45{\%} savings). The foreseeable disadvantage to this drug is that it is only being marketed in the United States as a 0.3{\%} solution, whereas the other nonselective beta blockers are available in two concentrations (0.25{\%} and 0.5{\%}).",
author = "Christina Flaxel and Samples, {J. R.}",
year = "1991",
language = "English (US)",
volume = "10",
pages = "171--174",
journal = "Cutaneous and Ocular Toxicology",
issn = "1556-9527",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - New drugs in ophthalmology

T2 - Metipranolol

AU - Flaxel, Christina

AU - Samples, J. R.

PY - 1991

Y1 - 1991

N2 - Metipranolol has been approved for the treatment of ocular conditions in which lowering of the IOP is likely to be of therapeutic benefit, including in patients with ocular hypertension and with chronic open angle glaucoma. It is presently marketed in 5 ml or 10 ml plastic ophthalmic bottle dispensers with a controlled drop tip as Optipranolol in a 0.3% concentration only. Metipranolol has been found to be equal in efficacy to 0.25% timolol. The major benefit to this drug is its potential savings over the other currently available beta blockers. For example, a 10 ml bottle of Timoptic 0.5% costs approximately $27.44 while a 10 ml bottle of Optipranolol costs $12.50 (a 45% savings). The foreseeable disadvantage to this drug is that it is only being marketed in the United States as a 0.3% solution, whereas the other nonselective beta blockers are available in two concentrations (0.25% and 0.5%).

AB - Metipranolol has been approved for the treatment of ocular conditions in which lowering of the IOP is likely to be of therapeutic benefit, including in patients with ocular hypertension and with chronic open angle glaucoma. It is presently marketed in 5 ml or 10 ml plastic ophthalmic bottle dispensers with a controlled drop tip as Optipranolol in a 0.3% concentration only. Metipranolol has been found to be equal in efficacy to 0.25% timolol. The major benefit to this drug is its potential savings over the other currently available beta blockers. For example, a 10 ml bottle of Timoptic 0.5% costs approximately $27.44 while a 10 ml bottle of Optipranolol costs $12.50 (a 45% savings). The foreseeable disadvantage to this drug is that it is only being marketed in the United States as a 0.3% solution, whereas the other nonselective beta blockers are available in two concentrations (0.25% and 0.5%).

UR - http://www.scopus.com/inward/record.url?scp=0025948510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025948510&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0025948510

VL - 10

SP - 171

EP - 174

JO - Cutaneous and Ocular Toxicology

JF - Cutaneous and Ocular Toxicology

SN - 1556-9527

IS - 3

ER -